SOLIGENIX, INC. Financing Interest Expense
SOLIGENIX, INC. (SNGX) reported Financing Interest Expense of $498 for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-15.
Discontinued › Expense Statement › Interest Expense
us-gaap:FinancingInterestExpense · last filed 2020-05-15
- SOLIGENIX, INC. financing interest expense for the quarter ending 2020-03-31 was $498.00.
| Period end | Financing Interest Expense 3 month |
|---|---|
| 2020-03-31 | $498.00 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |